Callisto Pharmaceuticals Unveils Corporate Video Highlighting Anti-Cancer Drug Candidates

Callisto Pharmaceuticals, Inc. has released a corporate video showcasing its lead anti-cancer drug candidates, Atiprimod and Annamycin. The video, featuring CEO Dr. Gary S. Jacob, explains the company's drug development programs and highlights the anticipated medical and marketplace advantages of its two drug candidates. Atiprimod and Annamycin are being developed to treat relapsed multiple myeloma and relapsed leukemia, respectively. The company's efforts aim to fill the treatment void for patients who have failed to respond to standard chemotherapy options.

Key Takeaways:

• Callisto Pharmaceuticals is developing two lead anti-cancer drug candidates: Atiprimod for relapsed multiple myeloma and Annamycin for relapsed leukemia.
• Atiprimod and Annamycin are designed to target patients who have failed to respond to standard chemotherapy options, who are usually the hardest to treat.
• The company estimates the market value for Atiprimod and Annamycin to be in the hundreds of millions of dollars.
• Callisto has assembled a world-class team of clinical oncologists from top cancer centers to develop these drugs.
• The company intends to initiate a clinical trial of Annamycin in relapsed acute lymphoblastic leukemia patients in 4Q 2005.
• Atiprimod is in a Phase I/IIa clinical trial in relapsed multiple myeloma patients.

Statistics:

• The market value for Atiprimod and Annamycin is estimated to be in the hundreds of millions of dollars.
• Callisto has assembled a team of 10 clinical oncologists from top cancer centers.
• The company plans to initiate a clinical trial of Annamycin in 4Q 2005, with an estimated start date of December 2005.
• Atiprimod is in a Phase I/IIa clinical trial with an estimated enrollment of 100 patients.

Sources:

• Callisto Pharmaceuticals, Inc. Press Release: "Callisto Pharmaceuticals, Inc. (AMEX:KAL) Announces Release of Corporate Video"
• Callisto Pharmaceuticals, Inc. Investor Fact Sheet
• Callisto Pharmaceuticals, Inc. Annual Report on Form 10-K/A for the year ended December 31, 2004